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tuberculosis (TB), and 1.3 million died because of
TB [1]. In their most recent Global TB Report, the
World Health Organization (WHO) raised two major
concerns for TB control. First, of the estimated 8.6
million cases, nearly 3 million cases were deemed
‘missing’ either because they were not diagnosed
or not notified to health systems. Secondly, the
alarming rise of multidrug-resistant TB (MDR-TB),
where a majority of cases with MDR-TB are still
not being detected [1].
Undiagnosed cases and mismanaged patients are
powerful drivers of the global TB epidemic, and are
strongly associated with risk of mortality and drug-
resistance. The WHO report also raised concern
over too many TB patients not getting the high
quality TB care that they deserve. This is especially
true in the private sector, which is a dominant pro-
vider of medical care in many countries [2,3].
All patients with TB, regardless of where they
live or who they seek care from, should receive
the same quality of care, backed by sound evi-
dence. And patients with TB need an early and
accurate diagnosis, including screening for drug-
resistance; rapid initiation on an internationally-
recommended drug combination with quality-
assured drugs; adequate counseling about issues
such as medication adherence, side effects of
drugs, and diet; and a customized package of mea-
sures that can support the patient during 6 months
of treatment.
First published in 2006, the International Stan-
dards of TB Care (ISTC) outlined the standards for
quality TB care [4]. ISTC was envisioned to be a liv-
ing document, and would stay abreast of new
advances and policies. The 2nd Edition of ISTCwas published in 2009, and the 3rd Edition was pub-
lished on World TB Day 2014 [5].
The standards in the ISTC are all supported by
existing WHO guidelines, backed by evidence from
systematic reviews. The 3rd Edition of ISTC has
been endorsed by organizations that include the
WHO, the American Thoracic Society, FHI 360,
Japan Anti-tuberculosis Association, KNCV Tuber-
culosis Foundation, Management Sciences for
Health, and the International Union against Tuber-
culosis and Lung Disease [5].
The ISTC standards describe a widely accepted
level of care that all practitioners, public or pri-
vate, should seek to achieve in managing patients
who have TB, or are suspected of having TB. The
21 Standards included in the 3rd Edition of ISTC
are as follows.
1. Standards for diagnosis
Standard 1. To ensure early diagnosis, providers
must be aware of individual and group risk factors
for tuberculosis (TB) and perform prompt clinical
evaluations and appropriate diagnostic testing for
persons with symptoms and findings consistent with
TB.
Standard 2. All patients, including children, with
unexplained cough lasting two or more weeks or
with unexplained findings suggestive of TB on chest
radiographs should be evaluated for TB.
Standard 3. All patients, including children, who
are suspected of having pulmonary TB and are
capable of producing sputum should have at least
two sputum specimens submitted for smear
microscopy or a single sputum specimen for Xpert
MTB/RIF (Cepheid Inc., California) testing in a
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drug-resistance, who have HIV risks, or who are
seriously ill should have Xpert MTB/RIF performed
as the initial diagnostic test. Blood-based serologic
tests and interferon gamma release assays should
not be used for diagnosis of active TB.
Standard 4. For all patients, including children,
suspected of having extrapulmonary TB, appropri-
ate specimens from the suspected sites of involve-
ment should be obtained for microbiological and
histological examination. An Xpert MTB/RIF test is
recommended as the preferred initial microbiolog-
ical test for suspected tuberculous meningitis
because of the need for a rapid diagnosis.
Standard 5. In patients suspected of having pul-
monary TB whose sputum smears are negative,
Xpert MTB/RIF and/or sputum cultures should be
performed. Among smear and Xpert MTB/RIF-nega-
tive persons with clinical evidence strongly sugges-
tive of TB, anti-tuberculosis treatment should be
initiated after collection of specimens for culture
examination.
Standard 6. For all children suspected of having
intrathoracic (i.e., pulmonary, pleural, and medi-
astinal or hilar lymph node) TB, bacteriological
confirmation should be sought through examination
of respiratory secretions (expectorated sputum,
induced sputum, gastric lavage) for smear micros-
copy, an Xpert MTB/RIF test and/or culture.
2. Standards for treatment
Standard 7. To fulfill her/his public health respon-
sibility, as well as responsibility to the individual
patient, the provider must prescribe an appropri-
ate treatment regimen, monitor adherence to the
regimen and, when necessary, address factors
leading to interruption or discontinuation of the
treatment. Fulfilling these responsibilities will
likely require coordination with local public health
services and/or other agencies.
Standard 8. All patients who have not been
treated previously and who do not have other risk
factors for drug-resistance should receive a WHO-
approved first-line treatment regimen using quality
assured drugs. The initial phase should consist of
two months of isoniazid, rifampicin, pyrazinamide
and ethambutol. The continuation phase should
consist of isoniazid and rifampicin given for
4 months. The doses of anti-tuberculosis drugs used
should conform to WHO recommendations. Fixed
dose combination drugs may provide a more conve-
nient form of drug administration.
Standard 9. A patient-centered approach to
treatment should be developed for all patients inorder to promote adherence, improve quality of
life, and relieve suffering. This approach should
be based on the patient’s needs and mutual respect
between the patient and the provider.
Standard 10. Response to treatment in patients
with pulmonary TB (including those with TB
diagnosed by a rapid molecular test) should be
monitored by follow-up sputum smear microscopy
at the time of completion of the initial phase of
treatment (2 months). If the sputum smear is posi-
tive at completion of the initial phase, sputum
microscopy should be performed again at 3 months
and, if positive, rapid molecular drug-sensitivity
testing (line probe assays or Xpert MTB/RIF) or
culture with drug-susceptibility testing should be
performed. In patients with extrapulmonary TB
and in children, the response to treatment is best
assessed clinically.
Standard 11. An assessment of the likelihood of
drug-resistance, based on a history of prior treat-
ment, exposure to a possible source case having
drug-resistant organisms, and the community prev-
alence of drug-resistance (if known), should be
undertaken for all patients. Drug susceptibility
testing should be performed at the start of therapy
for all patients at a risk of drug-resistance. Patients
who remain sputum smear-positive at the comple-
tion of 3 months of treatment, patients in whom
treatment has failed, and patients who have been
lost to follow-up, or relapsed following one or more
courses of treatment should always be assessed for
drug-resistance. For patients in whom drug-resis-
tance is considered to be likely, an Xpert MTB/RIF
test should be the initial diagnostic test. If rifampi-
cin resistance is detected, culture and testing for
susceptibility to isoniazid, fluoroquinolones and
second-line injectable drugs should be performed
promptly. Patient counseling and education, as
well as treatment with an empirical second-line
regimen, should begin immediately to minimize
the potential for transmission. Infection control
measures appropriate to the setting should be
applied.
Standard 12. Patients with or highly likely to
have TB caused by drug-resistant (especially
MDR/XDR) organisms should be treated with spe-
cialized regimens containing quality-assured sec-
ond-line anti-tuberculosis drugs. The doses of
anti-tuberculosis drugs should conform to WHO
recommendations. The regimen chosen may be
standardized or based on presumed or confirmed
drug susceptibility patterns. At least five drugs–
pyrazinamide and four drugs to which the organ-
isms are known or are presumed to be susceptible,
including an injectable agent – should be used in a
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which the organisms are known or are presumed
to be susceptible, should be used in the continua-
tion phase. Treatment should be given for at least
18–24 months beyond culture conversion. Patient-
centered measures, including observation of
treatment, are required to ensure adherence.
Consultation with a specialist experienced in the
treatment of patients with MDR/XDR TB should be
obtained.
Standard 13. An accessible, systematically main-
tained record of all medications given, bacterio-
logic response, outcomes, and adverse reactions
should be maintained for all patients.
3. Standards for addressing HIV infection
and other co-morbid conditions
Standard 14. HIV testing and counseling should be
conducted for all patients with, or suspected of
having, TB unless there is a confirmed negative test
within the previous two months. Because of the
close relationship of TB and HIV infection, inte-
grated approaches to prevention, diagnosis and
treatment of both TB and HIV infection are recom-
mended in areas with high HIV prevalence. HIV
testing is of special importance as part of routine
management of all patients in areas with a high
prevalence of HIV infection in the general popula-
tion, in patients with symptoms and/or signs of
HIV-related conditions, and in patients having a
history suggestive of high risk of HIV exposure.
Standard 15. In persons with HIV infection and TB
who have profound immunosuppression (CD4 counts
less than 50 cells/mm3), ART should be initiated
within 2 weeks of beginning treatment for TB unless
tuberculous meningitis is present. For all other
patients with HIV and TB, regardless of CD4 counts,
antiretroviral therapy should be initiated within
8 weeks of beginning treatment for TB. Patients
with TB and HIV infection should also receive
cotrimoxazole as a prophylaxis for other infections.
Standard 16. Persons with HIV infection who,
after careful evaluation, do not have active TB
should be treated for presumed latent TB infection
with isoniazid for at least 6 months.
Standard 17. All providers should conduct a
thorough assessment for co-morbid conditions and
other factors that could affect TB treatment
response or outcome and identify additional ser-
vices that would support an optimal outcome for
each patient. These services should be incorpo-
rated into an individualized plan of care that
includes assessment of and referrals for treatment
of other illnesses. Particular attention should bepaid to diseases or conditions known to affect
treatment outcome, for example, diabetes melli-
tus, drug and alcohol abuse, undernutrition, and
tobacco smoking. Referrals to other psychosocial
support services or to such services as antenatal
or well-baby care should also be provided.
4. Standards for public health and
prevention
Standard 18. All providers should ensure that per-
sons in close contact with patients who have infec-
tious TB are evaluated and managed in line with
international recommendations. The highest prior-
ity contacts for evaluation are: (1) Persons with
symptoms suggestive of TB; (2) Children aged
<5 years; (3) Contacts with known or suspected
immunocompromised states, particularly HIV
infection; and (4) Contacts of patients with MDR/
XDR TB.
Standard 19. Children <5 years of age and per-
sons of any age with HIV infection who are close
contacts of a person with infectious TB, and who,
after careful evaluation, do not have active TB,
should be treated for presumed latent TB infection
with isoniazid for at least six months.
Standard 20. Each healthcare facility caring for
patients who have or are suspected of having infec-
tious TB should develop and implement an appro-
priate TB infection control plan to minimize
possible transmission of M. tuberculosis to patients
and healthcare workers.
Standard 21. All providers must report both new
and re-treatment TB cases and their treatment
outcomes to local public health authorities, in con-
formance with applicable legal requirements and
policies.
5. Translation of standards into practice
While the updated, 3rd edition of ISTC is a
welcome development, its impact will depend on
adequate dissemination, implementation, and
evaluation. To begin with, national or regional
adaptations of the ISTC can help, such as the
European Union Standards for TB Care [6], and
Standards of TB Care in India [7]. Engagement of
and endorsement by chest societies and private
sector physician associations may also help local
uptake. Indeed, the ISTC has been endorsed by
many national and regional professional societies.
ISTC training sessions have been organized in
several countries, and training materials and mod-
ules are freely available (www.istcweb.org), but to
reach general physicians and care providers at the
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pathic practitioners), simplification of the ISTC
document is necessary to make the standards less
academic and more practical. Mobile phone ver-
sions of the most critical elements of ISTC might
help expand the reach, and this is now available.
Since chest physicians and pulmonologists are
often key opinion makers in their local medical
communities and social networks, their active
involvement in training (e.g., as master trainers)
might have a positive influence on general practi-
tioners who look up to them for continuing educa-
tion. Managed care organizations and health
insurance programs could consider reimbursing
physicians who explicitly document TB care that
is in line with ISTC.
In unregulated private markers, where private
practitioners are rarely engaged with the TB con-
trol program, there is a need for intermediary
agencies or social enterprises that can liaise
between the private sector and the national TB
programs. In India, a ‘‘Private Provider Interface
Agency’’ (PPIA) model is now being tried out on a
pilot basis [8]. PPIAs are agencies that aggregate
healthcare providers, educate them on standards
for TB care, incentivize them to diagnose and treat
TB as per established standards, monitor adher-
ence to the standards, and use information and
communication technologies to notify cases,
improve treatment adherence, and make perfor-
mance-based payments.
Lastly, there is a need to develop systems to
assess quality of TB care as a key indicator in global
TB control [9]. Recently, standardized patients
(mystery clients) were used in India to examine
quality of care for angina, asthma and dysentery
[10]. In this study, correct diagnoses were rare,
and incorrect treatments were widely prescribed,
in the private, informal and public sectors. Unlike
prescription audits and hypothetical vignettes,
which measure clinical knowledge and compe-
tence, the standardized patient approach has been
shown to accurately assess provider practice (i.e.,
what physicians actually do). Efforts are now under
way to evaluate the standardized patient approach
to assessment of quality of TB care in India, and
will, hopefully, pave the way for such work in other
countries.
Overall, there is much work to be done to
improve the quality of TB care. Initiatives like the
ISTC need to be combined with good disseminationand translational work at the country level (e.g.,
PPIA model in India), coupled with sound measure-
ment approaches (e.g., standardized patients) to
see whether standards can actually change prac-
tice and improve patient outcomes.
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